19 - 20 May 2021
11th Annual Vaccines World Summit 2021
Virtual
Don't Miss Out on Vaccines World Summit 2021
500+
High Profile Attendees
50+
Organizations
50+
Expert Speakers
2+
Days of Networking
The Concept
Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025. The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.
Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration.
Conference Agenda
11th Annual Vaccines World Summit 2021 brings together the entire vaccines industry value chain including international and local vaccine players, government health authorities, regulators, academics & research institutions and solution providers to share knowledge, grow networks and form partnerships. Take your first step towards entrenching yourself within the vaccines community, get your copy of the brochure!
Register Now!
2021 Speakers
Rajinder Kumar Suri DCVMN
CEODCVMNRajinder Kumar Suri joined DCVMN (Developing Countries Vaccine Manufacturers Network) as CEO w.e.f. Jan 15th, 2021. Before this, he was donning the hat of Chief Executive-Biologicals, Panacea Biotec Ltd. Rajinder has over 40 years of rich experience in Pharmaceuticals & Biological products in Indian & International markets out of which over 24 years’ experience at the top management level including four years on the Board of Directors of the Indian subsidiary of Sanofi Pasteur. The remaining 19 years were with Pharma out of which 16 years with Lupin. Mr. Suri brings with him over 3 years of consulting experience as CEO & Senior Advisor, Arete Business Advisors.
Rajinder has been Member-Policy & Planning Committee (PPC), an advisory body to GAVI Board, representing DCVMN from October 2013 till June 2017, as also a Member of the GAVI Steering Committee for Supply & Procurement Strategy. He has played a lead role in negotiations & interactions with the Ministry of Health, Government of India, UN agencies, and other Global organizations like WHO, UNICEF, Bill & Melinda Gates Foundation, Clinton Health Access Initiative & several others. Rajinder is also a former Member Executive Committee & Vice-President, DCVMN for a period of two years from Oct. 2014 - 2016.
Dominique Maugeais Gavi, the Vaccine Alliance
Vaccine Manufacturing ExpertGavi, the Vaccine AllianceSwitzerland
Martin Friede World Health Organization (WHO)
LeadershipWorld Health Organization (WHO)SwitzerlandMartin Friede leads the vaccine research unit at the World Health Organization in Geneva, Switzerland. In this position Dr. Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and priorities, and assistance to countries to establish vaccine R&D and production. Prior to this position he held several positions within WHO including leading the organization’s technology transfer activities as well as leading the research into therapeutic interventions for Ebola.
Prior to joining WHO, Dr. Friede held several senior management positions in the vaccine industry. Dr. Friede earned his Ph.D. in Biochemistry from the University of Cape Town.
Raches Ella Bharat Biotech
Project Lead: SARS-CoV-2 VaccineBharat BiotechIndia
Etleva Kadilli UNICEF
Director, Supply DivisionUNICEFCopenhagen, DenmarkEtleva (Eva) Kadilli is Director of UNICEF’s Supply Division, based in Copenhagen, Denmark, and oversees UNICEF's global supply chain functions with an annual expenditure exceeding USD 3.8 billion. In this capacity, she leads the effective, efficient, and ethical provision of essential and emergency supplies for children, through direct UNICEF programs, and in cooperation with national governments and partners.
Responsible for the management of UNICEF’s supply response to humanitarian crises, Ms. Kadilli is presently leading the organization’s strategic procurement and logistics emergency response to the COVID-19 pandemic. In this capacity, she represents UNICEF in the UN COVID Supply Chain Task Force and also represents the organization in a number of other global forums, including interagency engagements on UN procurement reform, and an alternate member of the Board of Gavi, the Vaccine Alliance. Ms. Kadilli also sits on Gavi’s Audit and Finance Committee, and Market Sensitive Decisions Committee.
A UNICEF staff member for nearly 25 years, Ms. Kadilli has held several roles at the headquarters and field levels, as well as in development and emergency contexts, including Albania, the Democratic Republic of the Congo (DRC), The Gambia, and Somalia. Ms. Kadilli has been with UNICEF’s Supply Division since 2011, where she previously held the position of Deputy Director, Supply Chain, overseeing teams responsible for contracting policy and procedures, quality assurance, global logistics operations, and emergency response. Her other roles have included Chief of Contracting, responsible for procurement oversight and compliance; and Contract Manager and Medical Unit Team Leader for health technology supplies in support of MNCH and HIV/AIDS programs, including during the 2014-2016 Ebola outbreak.
Matthew Downham CEPI
Sustainable Manufacturing LeadCEPIUnited KingdomDr. Downham studied a Bachelor of Sciences degree (with honors) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim (DE). He then completed a Ph.D. in biochemical engineering (Birmingham University, UK), a post-doctoral research fellowship - bio-molecular sciences (Liverpool John Moores University, UK), and a post-graduate certificate in further/higher education
(Bolton Institute, UK). He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT) & AstraZeneca (UK).
Dr. Downham worked on the preclinical and early clinical development of a vaccine, antibody, or enzyme therapies for infectious, hypertension, inflammatory, and oncology indications. He was a European Registered Toxicologist (2010-18); Chair, Vaccines Europe Influenza working group (2017-20); Treasurer, International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply task force (2017-20); Vice-Chair, IFPMA Convention on Biological Diversity working group (2018-20).
Dr. Downham has also co-authored 29 publications/abstracts and 3 international patents and in January 2021, joined the Coalition for Epidemic Preparedness Innovations (UK) as the Sustainable Manufacturing Lead.
Key Relevant Information:
BSc Hons Industrial Biology (London South Bank Polytechnic, UK & Boehringer Mannheim, DE), Ph.D. Biochemical Engineering (Birmingham University, UK), PGCE (Bolton Institute, UK), post-doctoral research fellowship – biomolecular sciences (Liverpool John Moores University, UK) and an EU Registered Toxicologist (Royal Society of Biology UK, 2010-‘18) 25 years international biopharmaceutical industry: Boehringer Mannheim (DE), Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT), AstraZeneca (UK).
Dr. Anh Wartel International Vaccine Institute
Deputy Director General, CAREInternational Vaccine InstituteKorea Dr. T. Anh Wartel has 20 years of experience in epidemiological studies, clinical research from phase I to phase IV studies, and CTD development. She earned her MD at the Paris XII Medical School, France, and completed a post-graduate diploma in Public Health from the University of Liverpool, UK. She has extensive experience in the fields of epidemiological and clinical research within both academia and the pharmaceutical industry during her 15 year-long career with Sanofi Pasteur before joining IVI in 2018. After having started her research career as a co-investigator in drugs and therapeutic vaccine trials in HIV infected patients at the French National Agency of Research on HIV/AIDS (ANRS) at Kremlin Bicetre University Hospital in Paris, she then joined Sanofi Pasteur in 2003. Her responsibilities grew over the course of 15 years to include Epidemiology and Clinical R&D activities (e.g., Japanese encephalitis, Pneumococcal Disease, Dengue Disease); Medical Affairs activities as the Regional Medical Expert for enteric, endemic, and travelers vaccines (e.g., rabies, cholera, typhoid fever, hepatitis A, yellow fever, dengue, Japanese encephalitis vaccines); and Country Medical Head for Vietnam and Cambodia. She joined IVI in September of 2018 as the Head of Clinical Development and Regulatory.
Neelima Dwivedi MSD
Senior Director - External Affairs, Market Access, PolicyMSDIndiaNeelima is a senior professional with over 25 years of experience in Corporate Affairs, Public Policy, CSR & Philanthropy. She has a strong blend of global and local expertise having played an instrumental role in developing government affairs strategies, policy advocacy, reputation management, and public-private partnerships at PepsiCo, MSD, DuPont & Monsanto where she has served as part of the country leadership team. Her last stint was at Microsoft, where she served as Group Head & Director, Government Affairs & Public Policy, and was responsible for driving Policy & Regulatory Affairs for Microsoft India, across all businesses.
Having worked in the challenging environment across these diverse industries, she understands that proactive stakeholder engagement, cultivating relationships & Issue Management are the important prerequisite of commercial success. Neelima has driven public-private partnership initiatives across several states in India. She has been part of several Govt’s Steering committees such as in Agriculture- 12th Five years plan on Agriculture Extension, & Public-Private Partnerships, Doubling Farmer’s income of MOA. She also contributed to the Food Processing Committee chaired by the Secretary Ministry of Food Processing and led several working groups & Advocacy committees of Industry Associations. She also participated in the national COVID-19 response core committee of Telemedicine.
Neelima has had an earlier stint with MSD India between 2013-2016 as Senior Director, Corporate Affairs. During her earlier stint, she also led MSD for Mothers in India which was a multimillion-dollar engagement & partnership with public health organizations. She also led initiatives across ASEAN countries as a special assignment to support Women Health Business at MSD.
Ofer Levy Boston Children's Hospital, Harvard Medical School
Director, Precision Vaccines Program, Division of Infectious DiseasesBoston Children's Hospital, Harvard Medical SchoolUSADr. Ofer Levy was born to and raised by the artist Benjamin Levy and music composer Hannah Levy in New York City, where he graduated from the Bronx High School of Science. After graduating from Yale College (B.S., Molecular Biophysics and Biochemistry), Dr. Levy entered the Medical Scientist (MD/Ph.D.) Training Program at New York University School of Medicine. There he earned his Ph.D. under the mentorship of Drs. Peter Elsbach and Jerrold Weiss, characterizing white blood cell (neutrophil)-derived antimicrobial proteins and peptides. Inspired by his wife Sharon’s example, he chose Pediatrics and completed both residency and fellowship (Infectious Diseases) at Boston Children’s Hospital. He is currently a Professor at Harvard Medical School as well as principal investigator, staff physician, and the Director of the Precisions Vaccine Program in the Division of Infectious Diseases, Boston Children’s Hospital.
The Precision Vaccines Program (PVP) is a platform to foster international collaboration between academia, government, and industry for the development of vaccine formulations optimized to protect vulnerable populations. The PVP is focused on modeling vaccine-induced human immune responses in vitro using a variety of platforms including three-dimensional microphysiologic systems as well as global molecular (“OMIC”) approaches to accelerate and de-risk development of vaccines optimized for populations with distinct immune responses, including those at the extremes of age who suffer the most infections.
He currently leads several NIH/NIAID-supported studies: (a) an Adjuvant Discovery Program contract, leveraging robotic and immunologic approaches to discover, characterize, and formulate novel small molecule adjuvants that may enhance vaccine responses of the young and the elderly; (b) an international Human Immunology Project Consortium effort employing systems biology to define biomarkers of neonatal vaccine immunogenicity, and (c) a number of coronavirus/COVID-related studies including a national effort to discover biomarkers of COVID disease severity as well as a project to discover and develop novel coronavirus vaccines. He lives in Cambridge, Massachusetts along with his wife Dr. Sharon Levy, and their three children.
Scots Roberts Altimmune
Chief Scientific OfficerAltimmuneUSADr. Scot Roberts has served as the Chief Scientific Officer (CSO) for Altimmune since December 2012. He has over two decades of experience managing scientific operations in the fields of cancer and infectious disease and has led drug development efforts for small molecules and biologics with a focus on viral vectors and antiviral therapies. Previously, as CSO for ImQuest BioSciences, Inc., he led scientific operations and business development initiatives. Prior to ImQuest, he held leadership positions at Wellstat Biologics Corporation including Director, Research and Development where he was responsible for the development of biological candidates in oncology including a clinical-stage asset. Dr. Roberts completed a post-doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology, and received his Ph.D. from the Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences. Dr. Roberts has authored numerous publications and is an inventor on a broad portfolio of patents.
Ramesh Mathur Senior Biological E
Senior Vice President and Head Biological EIndia
Jayesh Ranjan Government of Telangana
Principal Secretary, Industries & Commerce and Information TechnologyGovernment of Telangana IndiaJayesh Ranjan is a member of the Indian Administrative Service (IAS) of the 1992 batch and working in the state of Telangana. He holds a Masters Degree in Psychology from Delhi University, a degree in Business Management from the Indian Institute of
Management, Calcutta, and a Masters in Public Management from Lee Kuan Yew School of Public Policy, National University of Singapore. He has also done short courses from the University of Birmingham (on Environmental Policy Analysis), JICA the training Institute, Tokyo (on lake remediation), London School of Economics (on Globalization and Leadership), Kennedy School of Government, Harvard University (in Public Policy), and Swedish Institute, Stockholm (on Sustainability and CSR). He is the All-India topper of his IAS batch of 1992. He was awarded World Bank’s Social Capital Visiting Scholarship in 2002 and the British Government’s Gurukul Chevening Scholarship in 2005. He has done international consultancy assignments for the World Bank, UN-ESCAP, Sedatu project of Mexico, and for international NGOs working for Youth Issues like YES, Inc of the USA, and NMC from Italy. He is a part of the National Pool of
Jayesh Ranjan is the Principal Secretary of the Industries & Commerce, and Information Technology (IT) Departments of the Telangana government. His assignment involves developing policy frameworks, attracting new investments, identifying opportunities of utilizing IT in various government processes, and promoting, digital empowerment of the citizens. His last few assignments have been in the Industrial Promotion sector as Commissioner and MD of the Industries Department, Secretary in the Tourism Promotion Department, and Vice-Chairman of the Hyderabad Urban Development Authority (HUDA), all for 2-3 years each, and various rural assignments in different parts of the state for over 12 years, working in diverse sectors like Tribal Development, Natural Resources Management, Poverty Alleviation, and other related Social Development Sectors.
Arun Kumar CEPI
Preclinical Vaccines Development LeadCEPINorwayDr. Arun Kumar is the Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovation (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he worked on the universal influenza vaccine development program based on Self-amplifying messenger RNA technology. He has focused his career on the next-generation platform technologies for vaccine development and translational sciences. At CEPI, he currently leading global programs including preclinical development, Systems Immunology and also co-leading the CEPI Centralized Global Laboratory Network. He also manages various International collaborative activities. Arun holds a Ph.D. in Immunology and Infectious diseases from the University of Helsinki, Finland.
Remko Van Leeuwen INDIGO
Project CoordinatorINDIGONetherlands
Dr. Farshad Guirakhoo COVAXX and VAXXINITY
Chief Scientific OfficerCOVAXX and VAXXINITYUSA
Dr. Sanjay Singh Gennova Pharmaceuticals
CEOGennova PharmaceuticalsIndia
Ashish Sahai Serum Institute of India
Additional DirectorSerum Institute of IndiaIndia
Li Shi Shanghai Zerun Biotechnology
CEOShanghai Zerun BiotechnologyChina
Dr. Vickneshwaran Muthu Disease Control Division Ministry of Health, Malaysia
Senior Principal Assistant DirectorDisease Control Division Ministry of Health, MalaysiaMalaysia
Kapil Maithil Zydus Cadila
President & Head, Vaccines and DiagnosticsZydus CadilaIndia
Dr. Ming Ni Plasmid Virus R&D Department
Technical ManagerPlasmid Virus R&D DepartmentGenScript ProBioDr. Ming Ni received his doctoral degree from the University of Washington. He joined GenScript in January 2020 and has been responsible for technical support of the plasmid DNA platform. He led the plasmid DNA project to improve the yield and optimize purification steps. Before he joined GenScript, he was a full professor and department head of the Biomedical Engineering Department at Yachay Tech University. With over 50 peer-reviewed articles, 1600 citations, and 4 US patents, he is one of the most prolific scientists at GenScript.
Dr. Harshad Patil Interactive Research School for Health Affairs
ScientistInteractive Research School for Health AffairsIndiaAs a step forward towards contributing to vaccine research in India; Dr. Harshad joined Interactive Research School of Health Affairs, Bharati Vidyapeeth (Deemed to be University), Pune, where he is conducting research on chikungunya and respiratory syncytial virus vaccine development.
Previously, Dr. Harshad completed his post-doctoral research at UC Louvain, Brussels, Belgium under the supervision of Prof. dr. Rita Vanbever. The objective of his research was to increase the residence time of the monoclonal antibody and evaluating its efficacy after pulmonary delivery. Along with this, research was performed on evaluating the immune mechanisms elicited by AdvaxTM adjuvant in collaboration with the University of Groningen. The base of his post-doctoral success was entirely created during his Ph.D. under the supervision of Prof. Dr. Anke Huckriede. Here Dr. Harshad worked on the development of a stable adjuvanted inactivated whole influenza virus vaccine for pulmonary delivery and sublingual delivery. Research on these vaccine development projects helped him to gain knowledge in immunology, adjuvants, antigens, and delivery routes.
Before joining Ph.D., the research and practical skills that Harshad developed at Serum Institute of India and Ventri Biologicals helped him to perform his Ph.D. research experiments at a faster pace. He also gained valuable experience in Good Laboratory Practice, Good Manufacturing Practice, and viral vaccine quality control at Serum Institute of India, India’s pioneer vaccine manufacturing company.
2021 Sponsors & Partners
Become a Sponsor!
This event promises to be an opportunity to meet and network with vaccine companies from developed as well as developing countries, industry leaders, regulatory officials, academia, and network. Don't miss out on this opportunity and download the brochure to find out more.
Market Intelligence
Latest 2021 eBook: Therapeutic Prophylactic Vaccines Pipeline in Developing Economies
English 
简体中文 
日本語 
한국어 
繁體中文